For example, developing drugs like angiopoietin-2 inhibitors for patients receiving high-dose interleukin-2 therapy can avoid SCLS, a significant dose-limiting side effect, thereby preventing early withdrawal of IL-2 therapy. The gene discussed is ANGPT2; the disease is Systemic capillary leak syndrome.